Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Acute kidney injuries take the lead for A1M
October 2018
SHARING OPTIONS:

LUND, Sweden—A1M Pharma recently shared news that it had selected acute kidney injuries in conjunction with heart surgery as the key indication for further development of its drug candidate ROSgard. Following the completion of a Phase 1 trial in healthy individuals, a Phase 1b trial in individuals with acute kidney injuries is planned to assess safety and pharmacodynamic efficacy. A1M will continue working toward clinical development in preeclampsia and PRRT (kidney protection in conjunction with radiation therapy).
 
“There are currently no specific drug treatments for acute kidney injuries, an indication with exceptionally good prospects to swiftly document clinical efficacy. The commercial potential is also significant, and the regulatory development path is well defined,” noted Tobias Larsson Agervald, A1M Pharma’s incoming chief medical officer.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.